How does Eli Lilly (LLY) make money?

Eli Lilly (LLY) generates revenue primarily from Cardiometabolic Health, which accounted for 76.3% of total revenue in TTM through Q1 2026. The company reported $72.25B in revenue and converted 35% of it into net profit, equivalent to roughly $25.27B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Eli Lilly (LLY)?

Eli Lilly (LLY) reported a gross profit margin of 83.5% in TTM through Q1 2026, equivalent to $60.33B in gross profit on $72.25B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Eli Lilly (LLY)?

Eli Lilly (LLY) reported an operating profit margin of 45.9% in TTM through Q1 2026, equivalent to $33.14B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Eli Lilly (LLY)?

Eli Lilly (LLY) reported a net profit margin of 35% in TTM through Q1 2026, equivalent to $25.27B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Eli Lilly (LLY) profitable?

Yes. Eli Lilly (LLY) reported $25.27B in net income for TTM through Q1 2026, with a net profit margin of 35%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Eli Lilly (LLY) invest in research and development?

Eli Lilly (LLY) invested $14.11B in research and development during TTM through Q1 2026, roughly 19.5% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Eli Lilly (LLY) spend on capital expenditures?

Eli Lilly (LLY) spent $6.90B on capital expenditures (CapEx) during TTM through Q1 2026, roughly 9.6% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Eli Lilly (LLY) generate?

Eli Lilly (LLY) generated $13.58B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 18.8%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Eli Lilly (LLY)?

Eli Lilly (LLY) had an effective tax rate of 18.8% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Eli Lilly (LLY)?

Eli Lilly (LLY) reports revenue across 5 reportable product segments, led by Cardiometabolic Health at 76.3% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Eli Lilly (LLY) generate most of its revenue?

UNITED STATES is the largest geographic market for Eli Lilly (LLY), accounting for 58.9% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Eli Lilly Makes Money: 2026 Visual Revenue Map

Eli Lilly (LLY) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 30, 2026).

Eli Lilly (LLY) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Eli Lilly (LLY) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Cardiometabolic Health	$55.15B	76.3%
Oncology	$9.71B	13.4%
Immunology	$5.23B	7.2%
Neuroscience	$1.43B	2%
Other Product, Total	$737.54M	1%
Total	$72.25B	100%

Cardiometabolic Health$55.15B
Oncology$9.71B
Immunology$5.23B
Neuroscience$1.43B
Other Product, Total$737.54M
Total$72.25B

Eli Lilly (LLY) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Eli Lilly (LLY), TTM through Q1 2026
Region	Revenue (USD)	% of total
UNITED STATES	$47.11B	58.9%
Non-US	$15.51B	19.4%
Europe	$12.82B	16%
JAPAN	$2.30B	2.9%
CHINA	$2.19B	2.7%
Total	$79.93B	100%

UNITED STATES
Non-US
Europe
JAPAN
CHINA
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Eli Lilly (LLY) reports revenue across 5 operating segments; the largest segment was Cardiometabolic Health at 76.3%, followed by Oncology (13.4%) and Immunology (7.2%). Separately, by end-market geography, UNITED STATES accounted for 58.9% of revenue, followed by Non-US (19.4%) and Europe (16%).

Frequently asked questions

Data & methodology

Eli Lilly (LLY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation